Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

摘要背景2 型糖尿病患者的骨折风险较高, 且不依赖于使用降糖药物. 此外, 降糖药物还可以直接
影响骨代谢. 最近, 已经发现使用二肽基肽酶‐4 抑制剂与较低的骨折发生率有关. 本meta …

Background Despite advancements in care, many people with type 2 diabetes do not meet
treatment goals; thus, development of new therapies is needed. We aimed to assess …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Metabolic homeostasis in mammals is tightly regulated by the complementary actions of
insulin and glucagon. The secretion of these hormones from pancreatic β-cells and α-cells …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …